Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study to evaluate the safety and efficacy of KSI-301 compared to standard of care Aflibercept in wet age-related macular degeneration

Trial Profile

A phase 2 study to evaluate the safety and efficacy of KSI-301 compared to standard of care Aflibercept in wet age-related macular degeneration

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs KSI 301 (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors Kodiak Sciences
  • Most Recent Events

    • 21 Dec 2018 According to a Kodiak Sciences media release, the company remain on track to begin enrollment in this study in the second quarter of 2019.
    • 21 Dec 2018 According to a Kodiak Sciences media release, as wet AMD is a more localized retinal disease with typically lower levels of VEGF compared to DME, the company has enhanced this pivotal study design to include evaluation of 20-week along with 16-week and 12-week dosing intervals in comparison to Eylea on its 8-week labeled regimen.
    • 03 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top